M&G PLC Has $10.82 Million Position in Gilead Sciences, Inc. $GILD

M&G PLC trimmed its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 6.6% in the third quarter, Holdings Channel.com reports. The firm owned 97,504 shares of the biopharmaceutical company’s stock after selling 6,864 shares during the quarter. M&G PLC’s holdings in Gilead Sciences were worth $10,823,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. Brighton Jones LLC boosted its holdings in shares of Gilead Sciences by 20.6% during the 4th quarter. Brighton Jones LLC now owns 14,359 shares of the biopharmaceutical company’s stock valued at $1,326,000 after acquiring an additional 2,450 shares in the last quarter. Bison Wealth LLC bought a new stake in shares of Gilead Sciences during the fourth quarter worth about $215,000. Sivia Capital Partners LLC grew its holdings in shares of Gilead Sciences by 16.8% during the second quarter. Sivia Capital Partners LLC now owns 4,182 shares of the biopharmaceutical company’s stock worth $464,000 after purchasing an additional 602 shares during the last quarter. Crewe Advisors LLC increased its stake in shares of Gilead Sciences by 24.3% in the second quarter. Crewe Advisors LLC now owns 726 shares of the biopharmaceutical company’s stock valued at $80,000 after buying an additional 142 shares during the period. Finally, Princeton Global Asset Management LLC raised its holdings in Gilead Sciences by 58.2% in the 2nd quarter. Princeton Global Asset Management LLC now owns 791 shares of the biopharmaceutical company’s stock valued at $88,000 after buying an additional 291 shares during the last quarter. Institutional investors and hedge funds own 83.67% of the company’s stock.

Gilead Sciences Stock Performance

NASDAQ:GILD opened at $154.98 on Tuesday. The company has a quick ratio of 1.31, a current ratio of 1.68 and a debt-to-equity ratio of 1.03. Gilead Sciences, Inc. has a twelve month low of $93.37 and a twelve month high of $157.29. The company has a fifty day moving average of $130.94 and a 200-day moving average of $122.68. The firm has a market capitalization of $192.28 billion, a P/E ratio of 22.89, a P/E/G ratio of 2.06 and a beta of 0.36.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.86 EPS for the quarter, topping analysts’ consensus estimates of $1.83 by $0.03. Gilead Sciences had a net margin of 28.90% and a return on equity of 49.46%. The business had revenue of $7.93 billion during the quarter, compared to analysts’ expectations of $7.68 billion. During the same period last year, the company posted $1.90 earnings per share. The business’s quarterly revenue was up 4.7% on a year-over-year basis. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. As a group, sell-side analysts anticipate that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, March 30th. Investors of record on Friday, March 13th will be paid a dividend of $0.82 per share. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.79. The ex-dividend date of this dividend is Friday, March 13th. This represents a $3.28 dividend on an annualized basis and a yield of 2.1%. Gilead Sciences’s dividend payout ratio (DPR) is currently 46.68%.

Analysts Set New Price Targets

Several analysts recently weighed in on GILD shares. Weiss Ratings reissued a “buy (b)” rating on shares of Gilead Sciences in a research note on Thursday, January 22nd. Deutsche Bank Aktiengesellschaft increased their price target on Gilead Sciences from $135.00 to $155.00 and gave the company a “buy” rating in a research note on Wednesday, February 11th. Wells Fargo & Company raised their price objective on Gilead Sciences from $150.00 to $165.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 11th. UBS Group increased their target price on shares of Gilead Sciences from $145.00 to $155.00 and gave the company a “buy” rating in a research report on Monday, January 26th. Finally, Mizuho raised their price target on shares of Gilead Sciences from $131.00 to $140.00 and gave the stock an “outperform” rating in a report on Friday, November 21st. Twenty-three investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $152.50.

Insider Transactions at Gilead Sciences

In related news, CFO Andrew D. Dickinson sold 3,000 shares of Gilead Sciences stock in a transaction on Thursday, January 15th. The shares were sold at an average price of $124.31, for a total value of $372,930.00. Following the completion of the sale, the chief financial officer owned 150,503 shares of the company’s stock, valued at approximately $18,709,027.93. This trade represents a 1.95% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Johanna Mercier sold 3,000 shares of the company’s stock in a transaction on Thursday, January 15th. The stock was sold at an average price of $124.31, for a total transaction of $372,930.00. Following the transaction, the insider owned 103,221 shares in the company, valued at approximately $12,831,402.51. The trade was a 2.82% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 288,891 shares of company stock worth $40,303,946 in the last three months. Insiders own 0.27% of the company’s stock.

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.